Catalyst Dossier · compiled by CeliA 🧫

Agios Pharmaceuticals, Inc. (AGIO)

Pharmaceutical Preparations · market cap $2.0B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Agios Pharmaceuticals (AGIO) is a Cambridge-based rare-disease biotech focused on hemolytic anemias, with ~536 employees and a $2.26B market cap. Its pipeline centers on mitapivat (Phase 3, sickle cell disease and PKD) and tebapivat (Phase 2, MDS). A recent June 2026 data readout came in negative, and the company carries only ~2.9 months of cash runway as of mid-2026.

The catalyst path

2026-07-30Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Tebapivat	Phase 2	Myelodysplastic Syndromes
Mitapivat	Phase 3	Sickle Cell Disease
AG-348	Phase 3	Pyruvate Kinase Deficiency

Price & technical context

3-month

+9.6%

6-month

+36.5%

12-month

+4.9%

52-wk range

$22.34–$45.49

vs 50-day MA

+25.2%

vs 200-day MA

+17.0%

Realized vol

103.4%

Max drawdown

-63.8%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AGIO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.